NxStage Medical Inc. (NSDQ:NXTM) took another leap along the path to profitability during the second quarter, posting a 20.9 percent revenues increase and shaving losses by 34 percent.
The Lawrence, Mass.-based home hemodialysis products maker reported net losses of $8.3 million, or 17 cents per diluted share, on sales of $44.0 million during the three months ended June 30. That compares with net losses of $12.5 million, or 27 cents per diluted share, during the same period last year.